Search
ALMB-0166
go.drugbank.com/drugs/DB17937InvestigationalIt was granted FDA orphan designation in November 2018.[L47067]
AGuIX
go.drugbank.com/drugs/DB18189InvestigationalAGuIX is an investigational brand product consisting of a polysiloxane matrix and gadolinium chelates.
Brimapitide
go.drugbank.com/drugs/DB15231InvestigationalBrimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Chimeric antigen receptor T-cells
go.drugbank.com/drugs/DB22146InvestigationalChimeric Antigen Receptor T-cells is under investigation in clinical trial NCT05225363 (Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian
Rivipansel
go.drugbank.com/drugs/DB12778InvestigationalRivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
Anisomycin
go.drugbank.com/drugs/DB07374ExperimentalAnisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria _Streptomyces griseolus_. This drug acts to inhibit bacterial protein and DNA synthesis.
ADVM-062
go.drugbank.com/drugs/DB18341ExperimentalADVM-062 is an adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin)
Disitamab vedotin
go.drugbank.com/drugs/DB17208InvestigationalDisitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]
Ixmyelocel-T
go.drugbank.com/drugs/DB17601InvestigationalIxmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.
Baloxavir
go.drugbank.com/drugs/DB15675InvestigationalBaloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).